Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Verbeken, Mathieu ^a   Suleman, Sultan ^a,b   Baert, Bram ^a   Vangheluwe, Elien ^a   Van Dorpe, Sylvia ^a   Burvenich, Christian ^a   Duchateau, Luc ^a   Jansen, Frans H ^c   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

^b JIMMA UNIVERSITY   (Ethiopia)

^c Fondation ACT ion Afrique   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEFAN; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; COARTESIANE; LUMARTEM; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; COMPUTER MODEL; DRUG IMPURITY; DRUG MARKETING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ULTRAVIOLET RADIATION; CHEMICAL ANALYSIS; CHEMISTRY; COMPUTER SIMULATION; METHODOLOGY;

ANTIMALARIALS; CHEMISTRY TECHNIQUES, ANALYTICAL; COMPUTER SIMULATION; DRUG STABILITY; ETHANOLAMINES; FLUORENES;

EID: 79952055566     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-51     Document Type: Article

References (28)

1. Efficacy and safety of artemether-lumefantrine (Coartem (R)) tablets (six-dose regimen) in African infants and children with acute) uncomplicated falciparum malaria. C Falade M Makanga Z Premji CE Ortmann M Stockmeyer PI de Palacios, Trans R Soc Trop Med Hyg 2005 99 459 467 10.1016/j.trstmh.2004.09.013 15837358 (Pubitemid 40521344)
2. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. C Hatz S Abdulla R Mull D Schellenberg I Gathmann P Kibatala HP Beck M Tanner C Royce, Trop Med Int Health 1998 3 498 504 10.1046/j.1365-3156.1998. 00250.x 9657513 (Pubitemid 28283576)
3. Concerns about the privatization of public goods: A social dilemma analysis. M van Vugt, Soc Psychol Q 1997 60 4 355 367 10.2307/2787095
4. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. M van Vugt S Looareesuwan P Wilairatana R McGready L Villegas I Gathmann R Mull A Brockman NJ White F Nosten, Trans R Soc Trop Med Hyg 2000 94 545 548 10.1016/S0035-9203(00)90082-8 11132386
5. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. L vonSeidlein S Jaffar M Pinder M Haywood G Snounou B Gemperli I Gathmann C Royce B Greenwood, J Infect Dis 1997 176 1113 1116 10.1086/516524 9333180 (Pubitemid 27411064)
6. Recent advances in the discovery of haem-targeting drugs for malaria and schistosomiasis. KA de Villiers TJ Egan, Molecules 2009 14 2868 2887 10.3390/molecules14082868 19701131
7. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. M Traebert B Dumotier L Meister P Hoffmann M Dominguez-Estevez W Suter, Eur J Pharmacol 2004 484 41 48 10.1016/j.ejphar.2003. 11.003 14729380 (Pubitemid 38068532)
8. Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand. DK Pirker-Krassnig G Wernsdorfer J Sirichaisinthop C Rojanawatsirivet H Kollaritsch WH Wernsdorfer, Wien Klin Wochenschr 2004 116 47 52 10.1007/BF03040424 15683043 (Pubitemid 40065996)
9. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. WH Wernsdorfer B Landgraf V Kilimali G Wernsdorfer, Acta Trop 1998 70 9 15 10.1016/S0001-706X(97)00141-1 9707360 (Pubitemid 28254769)
10. Stability of essential drugs in the field: Results of a study conducted over a two-year period in Burkina Faso. F Ballereau T Prazuck I Schrive MT Lafleuriel D Rozec A Fisch C Lafaix, Am J Trop Med Hyg 1997 57 31 36 9242314 (Pubitemid 27305179)
11. Impurity profile: Significance in active pharmaceutical ingredient. SBKB Bari YS Jaiswal AA Shikhedkar, Eurasian J Anal Chem 2007 2 1 32 53
12. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. V Vergote C Burvenich C Van de Wiele B De Spiegeleer, J Pept Sci 2009 15 697 710 10.1002/psc.1167 19750489
13. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: The obestatin case. B De Spiegeleer V Vergote A Pezeshki K Peremans C Burvenich, Anal Biochem 2008 376 229 234 10.1016/j.ab.2008.02.014 18342612
14. Active drug substance impurity profiling - Part I. LC/UV diode array spectral matching. EC Nicolas TH Scholz, J Pharm Biomed Anal 1998 16 813 824 10.1016/S0731-7085(97)00131-3 9535194 (Pubitemid 28097409)
15. Pharmaceutical impurities - A mini review. J Roy, AAPS PharmSciTech 2002 3 rticle 6 10.1208/pt030206
16. ICH guidelines - International Conference on Harmonization, Q3A(R2) Impurities in new drug substances CPMP/ICH/2737/99. (October 2006). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002675.pdf [Accessed on 5 November 2010 at 11:06]
17. Authorized Lumefantrine USP Salmous Standard (Februari 2009). http://www.usp.org/pdf/EN/nonUSStandards/lumefantrine.pdf [Accessed on 24 October 2010 at 17:14]
18. Lumefantrine: Document QAS/06.186/FINAL (WHO Ph. Int. - July 2008). http://www.who.int/medicines/publications/pharmacopoeia/Lumef-monoFINALQAS06- 186-July08.pdf [Accessed on 24 October 2010 at 17:37]
19. Pharmaceutical applications of liquid chromatography coupled with mass spectrometry (LC/MS). H Lee, J Liq Chromatogr Relat Technol 2005 28 1161 1202 10.1081/JLC-200053022
20. Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection. ID Cesar FHA Nogueira GA Pianetti, J Pharm Biomed Anal 2008 48 951 954 10.1016/j.jpba.2008.05.022 18602241
21. Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical products. ID Cesar FHA Nogueira GA Pianetti, J Pharm Biomed Anal 2008 48 223 226 10.1016/j.jpba.2008.05.006 18571353
22. A Stability-Indicating LC Method for Lumefantrine. KR Patil VP Rane JN Sangshetti DB Shinde, Chromatographia 2009 69 375 379 10.1365/s10337-008-0894-x
23. LC-tandem mass spectrometry method for quantification of lumefantrine in human plasma and its application to bioequivalence study. V Munjal N Paliwal BK Chaursia B Varshney T Ahmed J Paliwal, Chromatographia 2010 71 505 510 10.1365/s10337-009-1446-8
24. ICH guidelines - International Conference on Harmonization, Q1A(R2) Stability testing of new drug substances and products CPMP/ICH/2736/99. (August 2003). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002651.pdf [Accessed on 5 November 2010 at 12:10]
25. Using in silico tools in a weight of evidence approach to aid toxicological assessment. CM Ellison JC Madden P Judson MTD Cronin, Mol Inf 2010 29 97 110 10.1002/minf.200900006
26. Computer-assisted methods in chemical toxicity prediction. CG Mohan T Gandhi D Garg R Shinde, Mini Rev Med Chem 2007 7 499 507 10.2174/ 138955707780619554 17504185 (Pubitemid 46845797)
27. The threshold of toxicological concern (TTC) in risk assessment. IC Munro AG Renwick B Danielewska-Nikiel, Toxicol Lett 2008 180 151 156 10.1016/j.toxlet.2008.05.006 18573621
28. Induction of protein droplet (alpha(2-mu)-globulin) nephropathy in male-rats after short-term dosage with 1,8-cineole and L-limonene. E Kristiansen C Madsen, Toxicol Lett 1995 80 147 152 10.1016/0378-4274(95)03390-7 7482582